Source: REUTERS

Hi-Tech Pharmacal: UPDATE 1-Akorn Inc's Hi-Tech Pharmacal infringes Allergan glaucoma drug patents

NEW YORK, Aug 4 (Reuters) - An Akorn Inc unit's proposed generic glaucoma drug infringed three Allergan Inc patents on its Lumigan topical treatment for the eye disease, a U.S. appeals court ruled on Tuesday.

Read full article »
Hi-Tech Pharmacal's Competitors | Hi-Tech Pharmacal's News | Hi-Tech Pharmacal's Financials
Stay up-to-date with the latest news on Hi-Tech Pharmacal
Est. Annual Revenue
$100-500M
Est. Employees
250-500
David S. Seltzer's photo - President & CEO of Hi-Tech Pharmacal

President & CEO

David S. Seltzer

CEO Approval Rating

70/100

Read more
Stay up-to-date with the latest news on Hi-Tech Pharmacal